Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ramucirumab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Paclitaxel and Ramucriumab | ACTIVE_COMPARATOR | - |
| Zanidatamab + Paclitaxel and Ramucirumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Paclitaxel | DRUG | 80 mg/m² |
| Ramucirumab | DRUG | 8 mg/kg |
| Zanidatamab | DRUG | Dose and schedule to be assigned at enrollment |
Inclusion Criteria: * Participants must have histologically or pathologically confirmed gastroesophageal adenocarcinoma (stomach, gastroesophageal junction or esophagus) that is unresectable or metastatic and which must be HER2 positive as confirmed by central testing using FDA-approved HER2 assay....
Ramucirumab is being studied for the treatment of Gastroesophageal Adenocarcinoma. It is currently in Phase 2 clinical development as part of a combination therapy for HER2-positive advanced Gastroesophageal Adenocarcinoma. The drug is being evaluated in a randomized, active-controlled trial.
Ramucirumab is a monoclonal antibody, indicated by its -mab suffix. It is being studied in combination with paclitaxel and zanidatamab for HER2-positive advanced Gastroesophageal Adenocarcinoma. The trial is biomarker-selected, focusing on patients with HER2-positive disease.
Ramucirumab is being developed by Jazz Pharmaceuticals plc, which is listed on the stock exchange under the ticker JAZZ. The company is conducting a Phase 2 clinical trial for this drug in Gastroesophageal Adenocarcinoma.
Ramucirumab is in Phase 2 clinical development. It is an investigational drug being studied for Gastroesophageal Adenocarcinoma and has not been approved for this indication. The ongoing trial is actively recruiting participants.
Ramucirumab is being studied in clinical trial NCT06043427, titled 'Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma'. This Phase 2 trial is recruiting 168 participants in Canada and is active but not yet completed.
No, Ramucirumab is not the same as zanidatamab. They are different drugs being studied in combination in the clinical trial NCT06043427. The trial compares paclitaxel and ramucirumab with or without zanidatamab in HER2-positive advanced Gastroesophageal Adenocarcinoma.